Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1835 - Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy in Gastric Cancer Patients with Peritoneal Metastasis

Date

09 Sep 2017

Session

Poster display session

Topics

Translational Research;  Gastric Cancer

Presenters

Hironori Yamaguchi

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

H. Yamaguchi1, Y. Sato2, H. Ishigami3, H. Oozawa4, M. Kurihara2, Y. Yatomi2, J. Kitayama5

Author affiliations

  • 1 Dept. Of Clinical Oncology, Jichi Medical University, 329-0498 - Tochigi/JP
  • 2 Dept. Of Clinical Laboratory, The University of Tokyo, 113-8654 - Tokyo/JP
  • 3 Dept. Of Chemotherapy, The University of Tokyo, 113-8654 - Tokyo/JP
  • 4 Dept. Of Surgery, Jichi Medical University, 329-0498 - Tochigi/JP
  • 5 Dept. Of Surgery, Jichi Medical University, Tochigi/JP
More

Resources

Abstract 1835

Background

The outcome of gastric cancer patients with peritoneal metastasis remains poor. We treated these patients with intraperitoneal and intravenous administration of paclitaxel plus oral tegafur/gimeracil/oteracil (S-1), followed by gastrectomy in responders. However, it remains to be determined whether gastrectomy contributes significantly to the survival benefit in good responders. It is also unclear how and when gastrectomy should be performed. Therefore, reliable biomarkers are urgently needed to predict the outcome of gastrectomy. Herein, we evaluated the clinical significance of carcinoembryonic antigen (CEA) mRNA levels in peritoneal lavage as a biomarker for the indication of conversion gastrectomy.

Methods

The peritoneal lavage of 68 patients who received the above regimen as induction chemotherapy was repeatedly collected via intraperitoneal access ports. Gastrectomy was considered when improvement of peritoneal metastasis was confirmed by a second laparoscopic examination with negative peritoneal cytolog. CEA and porphobilinogen deaminase (PBGD) mRNAs were chronologically quantified using the transcription reverse-transcription concerted reaction method. The CEA-mRNA Index (CmRI) was calculated as CEA mRNA/PBGD mRNA x 10,000.

Results

Thirty-nine patients received gastrectomy and 29 patients did not (median survival time (MST): 27.8 vs. 10.7 months, P 

Conclusions

The CmRI reflects the response of peritoneal metastases to induction intraperitoneal chemotherapy. It may be a useful biomarker to determine gastrectomy in gastric cancer patients with peritoneal metastasis.

Clinical trial identification

Legal entity responsible for the study

Hironori Yamaguchi

Funding

Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.